Refractory erythrodermic psoriasis in a child with an excellent outcome by using etanercept.
An Bras Dermatol
; 86(4 Suppl 1): S144-7, 2011.
Article
em En, Pt
| MEDLINE
| ID: mdl-22068796
Psoriasis affects 0.12% to 0.71% of all children. Erythrodermic psoriasis is an uncommon but serious disorder, occurring in less than 1.5% of cases. Tumor necrosis factor-alpha blockers (TNF-α) are a new class of drugs used to treat moderate to severe psoriasis refractory to conventional therapies. Etanercept is a TNFα receptor fusion protein, approved by the FDA for treating juvenile rheumatoid arthritis. We present the case of a 7-year-old suffering from plaque psoriasis since 8 months old which evolved into erythroderma refractory to cyclosporine and methotrexate. Patient responded excellently to etanercept, with no adverse side effects.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Psoríase
/
Imunoglobulina G
/
Metotrexato
/
Dermatite Esfoliativa
/
Receptores do Fator de Necrose Tumoral
/
Imunossupressores
Limite:
Child
/
Female
/
Humans
Idioma:
En
/
Pt
Revista:
An Bras Dermatol
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
Brasil
País de publicação:
Espanha